Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255506 | 0.83 | GABRP (0.47) | METGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9376173 | 0.79 | MAP4K4 (0.49) | CYP17A1MAP4K4MAPKAPK2AAK1SREBF2 | |
| SCHEMBL1137073 | 0.77 | MET (0.66) | MET | |
| SCHEMBL24167299 | 0.77 | EGLN2 (0.43) | CYP17A1METMAP4K4MAPK14SYK | |
| SCHEMBL28770642 | 0.77 | GABRP (0.38) | METMAPK14GABRPGABRDGABRA1 | |
| SCHEMBL23637704 | 0.76 | CYP17A1 (0.47) | CYP17A1MAPK14AAK1 | |
| SCHEMBL18295364 | 0.75 | CA1 (0.42) | CYP17A1MAP4K4MAPKAPK2SYKRET | |
| SCHEMBL1137300 | 0.74 | MET (0.67) | MET | |
| SCHEMBL1137415 | 0.74 | GABRP (0.42) | MAPK14GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL13193090 | 0.74 | CA12 (0.47) | CYP17A1MAP4K4MAPKAPK2SYKCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128199-B | Monocyclic heterocycles as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-07-24 | — | — | CN | disclosed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1737451-B1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714138-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| CN-101128199-A | Monocyclic heterocycles as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-02-20 | — | — | CN | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | CYP17A1 1922/4885MET 162/4885MAP4K4 40/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | CYP17A1 1922/4885MET 162/4885MAP4K4 40/4885 |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | CYP17A1 1922/4885MET 162/4885MAP4K4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.